WO2001034767A3 - 22 proteines humaines secretees - Google Patents

22 proteines humaines secretees Download PDF

Info

Publication number
WO2001034767A3
WO2001034767A3 PCT/US2000/030036 US0030036W WO0134767A3 WO 2001034767 A3 WO2001034767 A3 WO 2001034767A3 US 0030036 W US0030036 W US 0030036W WO 0134767 A3 WO0134767 A3 WO 0134767A3
Authority
WO
WIPO (PCT)
Prior art keywords
secreted proteins
human secreted
proteins
novel human
relates
Prior art date
Application number
PCT/US2000/030036
Other languages
English (en)
Other versions
WO2001034767A2 (fr
Inventor
Daniel R Soppet
George Komatsoulis
Yanggu Shi
Henrik S Olsen
Steven M Ruben
Original Assignee
Human Genome Sciences Inc
Daniel R Soppet
George Komatsoulis
Yanggu Shi
Henrik S Olsen
Steven M Ruben
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc, Daniel R Soppet, George Komatsoulis, Yanggu Shi, Henrik S Olsen, Steven M Ruben filed Critical Human Genome Sciences Inc
Priority to CA002387964A priority Critical patent/CA2387964A1/fr
Priority to AU17537/01A priority patent/AU1753701A/en
Priority to EP00980250A priority patent/EP1556401A2/fr
Priority to JP2001537464A priority patent/JP2003520033A/ja
Publication of WO2001034767A2 publication Critical patent/WO2001034767A2/fr
Publication of WO2001034767A3 publication Critical patent/WO2001034767A3/fr
Priority to US12/198,817 priority patent/US7968689B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

La présente invention concerne de nouvelles protéines humaines sécrétées ainsi que des acides nucléiques isolés contenant les régions codantes des gènes codant ces protéines. L"invention concerne également des vecteurs, des cellules hôtes, des anticorps, ainsi que des méthodes de recombinaison permettant la production de protéines humaines sécrétées. De plus, l"invention concerne des méthodes diagnostiques et thérapeutiques utiles pour diagnostiquer et pour traiter des maladies, des troubles et/ou des états liés à ces nouvelles protéines humaines sécrétées.
PCT/US2000/030036 1997-03-07 2000-11-01 22 proteines humaines secretees WO2001034767A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002387964A CA2387964A1 (fr) 1999-11-05 2000-11-01 22 proteines humaines secretees
AU17537/01A AU1753701A (en) 1999-11-05 2000-11-01 22 human secreted proteins
EP00980250A EP1556401A2 (fr) 1999-11-05 2000-11-01 22 proteines humaines secretees
JP2001537464A JP2003520033A (ja) 1999-11-05 2000-11-01 ２２個のヒト分泌タンパク質
US12/198,817 US7968689B2 (en) 1997-03-07 2008-08-26 Antibodies to HSDEK49 polypeptides

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US16357699P 1999-11-05 1999-11-05
US60/163,576 1999-11-05
US22136600P 2000-07-27 2000-07-27
US60/221,366 2000-07-27

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/030039 Continuation-In-Part WO2001034768A2 (fr) 1997-03-07 2000-11-01 15 proteines secretees humaines

Related Child Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2000/030045 Continuation-In-Part WO2001034626A1 (fr) 1997-03-07 2000-11-01 28 proteines secretees humaines
US10/100,683 Continuation-In-Part US7368531B2 (en) 1997-03-07 2002-03-19 Human secreted proteins

Publications (2)

Publication Number Publication Date
WO2001034767A2 WO2001034767A2 (fr) 2001-05-17
WO2001034767A3 true WO2001034767A3 (fr) 2002-05-02

Family

ID=26859765

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/030036 WO2001034767A2 (fr) 1997-03-07 2000-11-01 22 proteines humaines secretees

Country Status (5)

Country Link
EP (1) EP1556401A2 (fr)
JP (1) JP2003520033A (fr)
AU (1) AU1753701A (fr)
CA (1) CA2387964A1 (fr)
WO (1) WO2001034767A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004029087A2 (fr) * 2002-09-25 2004-04-08 Deutsches Institut für Ernährungsforschung Recepteurs du gout amer
EP2051077A3 (fr) 2003-10-07 2009-05-27 Millennium Pharmaceuticals, Inc. Molécules d'acide nucléique et protéines pour l'identification, évaluation, prévention, et thérapie du cancer de l'ovaire

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE GENBANK [online] 8 August 1995 (1995-08-08), FAUST ET AL., XP002948034, accession no. EMBL Database accession no. M11233 *
DATABASE SWISS-PROT [online] 28 December 1987 (1987-12-28), XP002948035, accession no. EMBL Database accession no. KHHUD *
FAUST ET AL.: "Cloning and sequence analysis of cDNA for human cathepsin D", PROC. NATL. ACAD. SCI., vol. 82, no. 15, 1985, pages 4910 - 4914, XP002948607 *

Also Published As

Publication number Publication date
AU1753701A (en) 2001-06-06
CA2387964A1 (fr) 2001-05-17
EP1556401A2 (fr) 2005-07-27
JP2003520033A (ja) 2003-07-02
WO2001034767A2 (fr) 2001-05-17

Similar Documents

Publication Publication Date Title
EP1053245A4 (fr) 45 proteines humaines secretees
WO1998039446A3 (fr) 70 proteines humaines secretees
WO1998039448A3 (fr) 186 nouvelles proteines secretees
WO1998040483A3 (fr) 28 proteines secretees par l'homme
WO1998031800A3 (fr) Proteines humaines
WO2001032910A3 (fr) 27 proteines humaines secretees
WO2001036432A3 (fr) 18 proteines secretees humaines
WO1998045712A3 (fr) 20 proteines humaines secretees
CY1111950T1 (el) 32 ανθρωπινες εκκρινομενες πρωτεϊνες
WO2001012776A3 (fr) 18 proteines secretees humaines
WO2001034768A3 (fr) 15 proteines secretees humaines
WO2000017222A8 (fr) 31 proteines humaines secretees
WO2000077026A8 (fr) 49 proteines secretees humaines
WO2000052136A3 (fr) Enzymes de glycosylation humaines
WO2000063230A3 (fr) 49 proteines secretees humaines
WO2000073323A3 (fr) Polynucléotides et polypeptides adam
WO2001062891A3 (fr) 207 proteines humaines secretees
EP1042342A4 (fr) 53 proteines secretees humaines
WO2000058339A3 (fr) 50 proteines humaines secretees
WO2001012775A8 (fr) 25 proteines secretees humaines
WO2000043495A3 (fr) Proteines humaines secretees (33)
WO2000061624A8 (fr) 48 proteines secretees humaines
WO2000061596A8 (fr) 50 proteines humaines secretees
WO2003052377A9 (fr) 41 proteines secretees humaines
WO2002099066A3 (fr) 20 proteines humaines secretees

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 2387964

Country of ref document: CA

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 537464

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000980250

Country of ref document: EP

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWP Wipo information: published in national office

Ref document number: 2000980250

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000980250

Country of ref document: EP